Overview

A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors

Status:
Completed

Trial end date:
2018-11-01

Target enrollment:

Participant gender:

Summary

By improved kidney dosimetry including biological effective dose and taking into account potential risk factors (especially for kidney toxicity), it might be possible to give an optimal and personalized treatment with 177Lu-DOTA-TATE to the patient with metastatic neuroendocrine tumor.

Phase:

Phase 2

Details

Lead Sponsor:

Lund University Hospital

Treatments:

Lutetium Lu 177 dotatate
Octreotide